https://orcid.org/0000-0002-5257-8678
Citations (57)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Samantha M. Ruff, Sameek Roychowdhury & Timothy M. Pawlik. (2023) The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma. Expert Opinion on Pharmacotherapy 24:7, pages 779-788.
Read now
Read now
Sakti Chakrabarti, Heidi D. Finnes & Amit Mahipal. (2022) Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management. Expert Opinion on Drug Metabolism & Toxicology 18:1, pages 85-98.
Read now
Read now
James Yu, Amit Mahipal & Richard Kim. (2021) Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. OncoTargets and Therapy 14, pages 5145-5160.
Read now
Read now
Haizhou Qiu, Chang Liu, Min Huang, Shu Shen & Wentao Wang. (2021) Prognostic Value of Combined CA19-9 with Aspartate Aminotransferase to Lymphocyte Ratio in Patients with Intrahepatic Cholangiocarcinoma After Hepatectomy. Cancer Management and Research 13, pages 5969-5980.
Read now
Read now
Margherita Rimini, Marco Puzzoni, Federica Pedica, Nicola Silvestris, Lorenzo Fornaro, Giuseppe Aprile, Eleonora Loi, Oronzo Brunetti, Caterina Vivaldi, Francesca Simionato, Patrizia Zavattari, Mario Scartozzi, Valentina Burgio, Francesca Ratti, Luca Aldrighetti, Stefano Cascinu & Andrea Casadei-Gardini. (2021) Cholangiocarcinoma: new perspectives for new horizons. Expert Review of Gastroenterology & Hepatology 15:12, pages 1367-1383.
Read now
Read now
Alessandro Rizzo, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola & Giovanni Brandi. (2021) Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities?. Expert Review of Gastroenterology & Hepatology 15:11, pages 1239-1240.
Read now
Read now
Qian Li, Feng Che, Yi Wei, Han-Yu Jiang, Yun Zhang & Bin Song. (2021) Role of noninvasive imaging in the evaluation of intrahepatic cholangiocarcinoma: from diagnosis and prognosis to treatment response. Expert Review of Gastroenterology & Hepatology 15:11, pages 1267-1279.
Read now
Read now
Matteo Repetto, Edoardo Crimini, Federica Giugliano, Stefania Morganti, Carmen Belli & Giuseppe Curigliano. (2021) Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions. Expert Review of Clinical Pharmacology 14:10, pages 1233-1252.
Read now
Read now
Héloïse Bourien, Angela Lamarca, Mairéad G McNamara, Richard A Hubner, Juan W Valle & Julien Edeline. (2021) Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. Expert Opinion on Investigational Drugs 30:9, pages 975-983.
Read now
Read now
Jose JG Marin & Rocio IR Macias. (2021) Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs. Expert Opinion on Investigational Drugs 30:7, pages 675-679.
Read now
Read now
Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico & Giovanni Brandi. (2021) FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. Expert Review of Gastroenterology & Hepatology 15:5, pages 567-574.
Read now
Read now
Alessandro Rizzo, Angela Dalia Ricci & Giovanni Brandi. (2021) Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opinion on Investigational Drugs 30:4, pages 343-350.
Read now
Read now
Articles from other publishers (45)
Surya K. De. (2024) Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth
Factor Receptors for Treatment of the Bile Duct Cancer. Current Medicinal Chemistry 31:6, pages 666-670.
Crossref
Crossref
Rabiya Ahsan, Mohd Muazzam Khan, Anuradha Mishra, Gazala Noor & Usama Ahmad. (2023) Protein Kinases and their Inhibitors Implications in Modulating Disease Progression. The Protein Journal 42:6, pages 621-632.
Crossref
Crossref
Dong Woo Shin. (2023) Treatment of Ampullary Adenocarcinoma. The Korean Journal of Gastroenterology 82:4, pages 159-170.
Crossref
Crossref
Jing-Yi Zhang, Ya-Tao Wang, Lu Sun, Sai-Qi Wang & Zhe-Sheng Chen. (2023) Synthesis and clinical application of new drugs approved by FDA in 2022. Molecular Biomedicine 4:1.
Crossref
Crossref
Sahin Coban, Omer Basar & William R. Brugge. 2023. The Pancreas. The Pancreas
1254
1263
.
Shuo Yuan, Dan‐Dan Shen, Rui Jia, Ju‐Shan Sun, Jian Song & Hong‐Min Liu. (2023) New drug approvals for 2022: Synthesis and clinical applications. Medicinal Research Reviews.
Crossref
Crossref
Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa, Atsushi Hirano, Hideki Kazuno, Satoshi Yamashita, Kosuke Egami, Yoshihiro Shibata, Ikuo Yamamiya, Fumiaki Yamashita, Yasuo Kodama, Kaoru Funabashi, Hiromi Kazuno, Toshiharu Komori, Satoshi Suzuki, Hiroshi Sootome, Hiroshi Hirai & Takeshi Sagara. (2023) Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use. ACS Medicinal Chemistry Letters 14:4, pages 396-404.
Crossref
Crossref
Anh Thu Nguyen & Hee-Kwon Kim. (2023) Recent Advances in Synthetic Routes to Azacycles. Molecules 28:6, pages 2737.
Crossref
Crossref
Jiajia Du, Xing Lv, Zunyi Zhang, Zhiyong Huang & Erlei Zhang. (2023) Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma. Frontiers in Immunology 14.
Crossref
Crossref
Rakesh Sahu, Praveen Sharma & Ajay Kumar. (2022) An Insight into Cholangiocarcinoma and Recent Advances in its Treatment. Journal of Gastrointestinal Cancer 54:1, pages 213-226.
Crossref
Crossref
A.S. Vodoleev & E.V. Gonchar. (2023) Cholangioscopy in the diagnosis and treatment of malignant neoplasms of the bile duct. Onkologiya. Zhurnal imeni P.A.Gertsena 12:5, pages 71.
Crossref
Crossref
Yong Jiang, Liyong Jiang, Feiyu Li, Qingbin Li, Shuai Yuan, Songhan Huang, Yingda Fu, Xiangyu Yan, Ji Chen, Hongxin Li, Shenhao Li & Jun liu. (2022) The epidemiological trends of biliary tract cancers in the United States of America. BMC Gastroenterology 22:1.
Crossref
Crossref
I. V. Savchenko, V. V. Breder, I. S. Stilidi, K. K. Laktionov, N. E. Kudashkin, A. V. Egorova & S. V. Chulkova. (2022) Second line drug therapy for biliary cancer. Meditsinskiy sovet = Medical Council:22, pages 136-147.
Crossref
Crossref
Paulina Chmiel, Katarzyna Gęca, Karol Rawicz-Pruszyński, Wojciech P. Polkowski & Magdalena Skórzewska. (2022) FGFR Inhibitors in Cholangiocarcinoma—A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?. Cells 11:23, pages 3929.
Crossref
Crossref
Maurizio Capuozzo, Mariachiara Santorsola, Loris Landi, Vincenza Granata, Francesco Perri, Venere Celotto, Oreste Gualillo, Guglielmo Nasti & Alessandro Ottaiano. (2022) Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology. International Journal of Molecular Sciences 23:23, pages 15124.
Crossref
Crossref
Heng Li, Hao-Zhe Ding, Yi-Lin Wang, Feng Zhang, Ya-Hao Song & Xiang-Jun Qiu. (2022) Validated UPLC-MS/MS Method for Determination of Futibatinib and Its Pharmacokinetics in Beagle Dogs. Journal of Chemistry 2022, pages 1-7.
Crossref
Crossref
Qingshun Zhu, Shengyong Zhai, Enkang Ge, Lei Li, Xuguang Jiao, Jinqiu Xiong, Guangxu Zhu, Yuanyuan Xu, Jianjun Qu & Zhengjiang Wang. (2022) Intrahepatic cholangiocarcinoma with gastric metastasis misdiagnosed as primary gastric cancer: A case report and literature review. Frontiers in Oncology 12.
Crossref
Crossref
A M U B Mahfuz, Md. Arif Khan, Suvro Biswas, Shamima Afrose, Shafi Mahmud, Newaz Mohammed Bahadur & Firoz Ahmed. (2022) In search of novel inhibitors of anti-cancer drug target fibroblast growth factor receptors: Insights from virtual screening, molecular docking, and molecular dynamics. Arabian Journal of Chemistry 15:7, pages 103882.
Crossref
Crossref
Anil K. Rengan & Crystal S. Denlinger. (2022) Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib. Journal of the National Comprehensive Cancer Network 20:5, pages 430-435.
Crossref
Crossref
Eleni-Myrto Trifylli, Evangelos Koustas, Nikolaos Papadopoulos, Panagiotis Sarantis, Georgios Aloizos, Christos Damaskos, Nikolaos Garmpis, Anna Garmpi & Michalis V. Karamouzis. (2022) An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma. Life 12:5, pages 665.
Crossref
Crossref
Anita Padmanabhanunni, Tyrone Brian Pretorius & Ashraf Kagee. (2022) The Health-Sustaining, Moderating, and Mediating Roles of Sense of Coherence in the Relationship between Fear of COVID-19 and Burnout among South African Teachers. International Journal of Environmental Research and Public Health 19:9, pages 5160.
Crossref
Crossref
Nina Beri. (2022)
Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring
FGFR2
gene rearrangements
. Future Oncology 18:11, pages 1391-1402.
Crossref
Crossref
Jelena Djokic Kovač, Aleksandra Janković, Aleksandra Đikić-Rom, Nikica Grubor, Andrija Antić & Vladimir Dugalić. (2022) Imaging Spectrum of Intrahepatic Mass-Forming Cholangiocarcinoma and Its Mimickers: How to Differentiate Them Using MRI. Current Oncology 29:2, pages 698-723.
Crossref
Crossref
Alessandro Rizzo, Angela Dalia Ricci, Antonio Cusmai, Silvana Acquafredda, Giuseppe De Palma, Giovanni Brandi & Gennaro Palmiotti. (2022) Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. Current Oncology 29:2, pages 551-564.
Crossref
Crossref
Felix Krenzien, Nora Nevermann, Alina Krombholz, Christian Benzing, Philipp Haber, Uli Fehrenbach, Georg Lurje, Uwe Pelzer, Johann Pratschke, Moritz Schmelzle & Wenzel Schöning. (2022) Treatment of Intrahepatic Cholangiocarcinoma—A Multidisciplinary Approach. Cancers 14:2, pages 362.
Crossref
Crossref
Daniel Walden, Cody Eslinger & Tanios Bekaii-Saab. (2022) Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements. Therapeutic Advances in Gastroenterology 15, pages 175628482211153.
Crossref
Crossref
Yingnan Yang, Zhuolong Tu, Chentao Ye, Huajie Cai, Shouzhang Yang, Xuehai Chen & Jinfu Tu. (2021) Site-specific metastases of gallbladder adenocarcinoma and their prognostic value for survival: a SEER-based study. BMC Surgery 21:1.
Crossref
Crossref
Lu Zou, Xuechuan Li, Xiangsong Wu, Jiujie Cui, Xuya Cui, Xiaoling Song, Tai Ren, Xusheng Han, Yidi Zhu, Huaifeng Li, Wenguang Wu, Xu’an Wang, Wei Gong, Liwei Wang, Maolan Li, Wan Yee Lau & Yingbin Liu. (2021) Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study. BMC Cancer 21:1.
Crossref
Crossref
Lindsay A. Hunter & Heloisa P. Soares. (2021) Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. Cancers 13:20, pages 5074.
Crossref
Crossref
Jun Fu, Qinjunjie Chen, Yuyan Yu, Wuyi You, Zongren Ding, Yuzhen Gao, Haitao Li & Yongyi Zeng. (2021) Impact of portal hypertension on short‐ and long‐term outcomes after liver resection for intrahepatic cholangiocarcinoma: A propensity score matching analysis. Cancer Medicine 10:20, pages 6985-6997.
Crossref
Crossref
Zeyu Zhang, Zhiming Wang & Yun Huang. (2021) A Bibliometric Analysis of 8,276 Publications During the Past 25 Years on Cholangiocarcinoma by Machine Learning. Frontiers in Oncology 11.
Crossref
Crossref
Brinda Balasubramanian, Simran Venkatraman, Tavan Janvilisri, Tuangporn Suthiphongchai, Siriporn Jitkaew, Jittiyawadee Sripa & Rutaiwan Tohtong. (2021) RTK25: A Comprehensive Molecular Profiling Strategy in Cholangiocarcinoma Using an Integrated Bioinformatics Approach. Pharmaceuticals 14:9, pages 898.
Crossref
Crossref
Alessandro Rizzo, Vincenzo Dadduzio, Lucia Lombardi, Angela Dalia Ricci & Gennaro Gadaleta-Caldarola. (2021) Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges. Current Oncology 28:5, pages 3393-3402.
Crossref
Crossref
Christopher Fabian Maier, Lei Zhu, Lahiri Kanth Nanduri, Daniel Kühn, Susan Kochall, May-Linn Thepkaysone, Doreen William, Konrad Grützmann, Barbara Klink, Johannes Betge, Jürgen Weitz, Nuh N. Rahbari, Christoph Reißfelder & Sebastian Schölch. (2021) Patient-Derived Organoids of Cholangiocarcinoma. International Journal of Molecular Sciences 22:16, pages 8675.
Crossref
Crossref
Hang Li, Li Chen, Guang-Yu Zhu, Xijuan Yao, Rui Dong & Jin-He Guo. (2021) Interventional Treatment for Cholangiocarcinoma. Frontiers in Oncology 11.
Crossref
Crossref
Carolin Czauderna, Martha M. Kirstein, Hauke C. Tews, Arndt Vogel & Jens U. Marquardt. (2021) Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma. Journal of Clinical Medicine 10:13, pages 2803.
Crossref
Crossref
Preawwalee Wintachai, Jing Quan Lim, Anchalee Techasen, Worachart Lert-itthiporn, Sarinya Kongpetch, Watcharin Loilome, Jarin Chindaprasirt, Attapol Titapun, Nisana Namwat, Narong Khuntikeo & Apinya Jusakul. (2021) Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma. Diagnostics 11:6, pages 999.
Crossref
Crossref
Marco Casadio, Francesca Biancaniello, Diletta Overi, Rosanna Venere, Guido Carpino, Eugenio Gaudio, Domenico Alvaro & Vincenzo Cardinale. (2021) Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine. International Journal of Molecular Sciences 22:11, pages 5613.
Crossref
Crossref
Alessandro Rizzo. (2021) Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. Medicina 57:5, pages 458.
Crossref
Crossref
Tomotake Shirono, Takashi Niizeki, Hideki Iwamoto, Shigeo Shimose, Hiroyuki Suzuki, Takumi Kawaguchi, Naoki Kamachi, Yu Noda, Shusuke Okamura, Masahito Nakano, Ryoko Kuromatu, Hironori Koga & Takuji Torimura. (2021) Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. Journal of Clinical Medicine 10:5, pages 987.
Crossref
Crossref
Alessandro Rizzo & Giovanni Brandi. (2021) Novel Targeted Therapies for Advanced Cholangiocarcinoma. Medicina 57:3, pages 212.
Crossref
Crossref
Takumi Onoyama, Wataru Hamamoto, Yuri Sakamoto, Shiho Kawahara, Taro Yamashita, Hiroki Koda, Soichiro Kawata, Yohei Takeda, Kazuya Matsumoto & Hajime Isomoto. (2021) Peroral Cholangioscopy-Guided Forceps Mapping Biopsy for Evaluation of the Lateral Extension of Biliary Tract Cancer. Journal of Clinical Medicine 10:4, pages 597.
Crossref
Crossref
Alessandro Rizzo, Angela Dalia Ricci & Giovanni Brandi. (2021) PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Cancers 13:3, pages 558.
Crossref
Crossref
Carissa Beaulieu, Arthur Lui, Dimas Yusuf, Zainab Abdelaziz, Brock Randolph, Eugene Batuyong, Sunita Ghosh, Oliver F. Bathe, Vincent Tam & Jennifer L. Spratlin. (2021) A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada. Current Oncology 28:1, pages 417-427.
Crossref
Crossref
Fan-li Zeng & Jing-fang Chen. (2021) Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma. Technology in Cancer Research & Treatment 20, pages 153303382110399.
Crossref
Crossref